Format

Send to

Choose Destination
See comment in PubMed Commons below
Rheum Dis Clin North Am. 2010 Aug;36(3):609-21. doi: 10.1016/j.rdc.2010.05.007.

The future of ANCA-associated vasculitis.

Author information

  • 1Department of Rheumatology and Clinical Immunology, Vasculitis Center, University Hospital Schleswig-Holstein, Bad Bramstedt, 24576 Bad Bramstedt, Germany. Holle@klinikumbb.de

Abstract

The introduction of cyclophosphamide for treatment and the detection of antineutrophil cytoplasmatic antibodies (ANCA) as a seromarker for ANCA-associated vasculitis (AAV) have been the most important milestones in the history of AAV. Nevertheless, there are still many issues to resolve to fully understand the pathogenesis of AAV and to improve patient outcomes. There is a need for diagnostic criteria; treatment strategies need further improvement to reduce the toxicity of conventional immunosuppressants such as cyclophosphamide. The elucidation of the genetic background in patients with AAV and the role of granulomatous lesions found in Wegener's granulomatosis are required to fully understand the pathophysiology of AAV.

Copyright 2010 Elsevier Inc. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk